--- title: "Northwest Biotherapeutics (NWBO) news: convertible notes" url: "https://aibio.space/companies/northwest-biotherapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NWBO convertible notes news: Northwest Biotherapeutics registers 40,325,000 shares tied to $4.9 million note. Northwest Biotherapeutics, Inc." --- NWBO Northwest Biotherapeutics, Inc. OTC · United States # Northwest Biotherapeutics (NWBO) news NWBO convertible notes news Financings · 2026-07-31 ## [Northwest Biotherapeutics registers 40,325,000 shares tied to $4.9 million note](https://aibio.space/news/northwest-biotherapeutics-registers-40-325-000-shares-tied-4-9-million/) Northwest Biotherapeutics signed a $4.9 million convertible note with a Yorkville fund on July 29, 2026. Net proceeds after original issue discount, a facility commitment fee and expenses are $4,655,000. ## Latest Northwest Biotherapeutics news 1. 2026-04-07 Mergers [Northwest Biotherapeutics reports October 2025 closing of Advent BioServices purchase](https://aibio.space/news/northwest-biotherapeutics-reports-october-2025-closing-advent/) The company bought the UK manufacturer from a seller controlled by its chief executive. Payment is due in installments over two years. 2. 2026-03-31 Distress [Northwest Biotherapeutics says 10-K is late over Advent BioServices accounting](https://aibio.space/news/northwest-biotherapeutics-says-10-k-late-advent-bioservices-accounting/) The company cites issues tied to its Advent BioServices acquisition, including differences between UK GAAP and US GAAP. The notice gives no date for the annual report. 3. 2026-01-02 Listings [Northwest Biotherapeutics holders approve raising authorized shares to 2,600,000,000](https://aibio.space/news/northwest-biotherapeutics-holders-approve-raising-authorized-shares-2/) Common stock authorized rises from 1,700,000,000 to 2,600,000,000 shares. The company filed the amendment in Delaware on December 30, 2025. ## Northwest Biotherapeutics at a glance - **Ticker**: NWBO - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $595,000 ### Related companies - [Agentix](https://aibio.space/companies/agentix/) OTC: AGTX - [Vyome Holdings](https://aibio.space/companies/vyome/) NASDAQ: HIND - [Neumora Therapeutics](https://aibio.space/companies/neumora-therapeutics/) NASDAQ: NMRA - [Lantern Pharma](https://aibio.space/companies/lantern-pharma/) NASDAQ: LTRN - [Pyxis Oncology](https://aibio.space/companies/pyxis-oncology/) NASDAQ: PYXS - [Regeneron Pharmaceuticals](https://aibio.space/companies/regeneron-pharmaceuticals/) NASDAQ: REGN - [Silo Pharma](https://aibio.space/companies/silo-pharma/) NASDAQ: SILO - [NOVACCESS GLOBAL INC.](https://aibio.space/companies/novaccess-global/) OTC: XSNX ### Also on OTC - [Nano Mobile Healthcare](https://aibio.space/companies/nano-mobile-healthcare/) VNTH - [Adastra Holdings](https://aibio.space/companies/adastra/) XTXXF - [Life Stem Genetics](https://aibio.space/companies/life-stem-genetics/) LIFS - [eFFECTOR Therapeutics](https://aibio.space/companies/effector-therapeutics/) EFTR - [LUDWIG ENTERPRISES, INC.](https://aibio.space/companies/ludwig-enterprises/) LUDG - [AFFYMAX INC](https://aibio.space/companies/affymax/) AFFY ## Northwest Biotherapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$28.8 million](https://www.sec.gov/Archives/edgar/data/1072379/000110465926043806/) | [$34.9 million](https://www.sec.gov/Archives/edgar/data/1072379/000110465926043806/) | | Net income (loss) | [-$60.2 million](https://www.sec.gov/Archives/edgar/data/1072379/000110465926043806/) | [-$83.8 million](https://www.sec.gov/Archives/edgar/data/1072379/000110465926043806/) | | Cash from operations | [-$44.8 million](https://www.sec.gov/Archives/edgar/data/1072379/000110465926043806/) | [-$57.0 million](https://www.sec.gov/Archives/edgar/data/1072379/000110465926043806/) | | Cash and equivalents | [$3.0 million](https://www.sec.gov/Archives/edgar/data/1072379/000110465926097188/) | [$2.2 million](https://www.sec.gov/Archives/edgar/data/1072379/000110465926043806/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $595,000. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Northwest Biotherapeutics Has Northwest Biotherapeutics sold convertible notes? Our latest story on this, dated Jul 31, 2026: "Northwest Biotherapeutics registers 40,325,000 shares tied to $4.9 million note". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/northwest-biotherapeutics-registers-40-325-000-shares-tied-4-9-million/). What is the ticker symbol of Northwest Biotherapeutics? Northwest Biotherapeutics, Inc. trades under the ticker NWBO on OTC. Where is Northwest Biotherapeutics listed? Northwest Biotherapeutics, Inc. is listed on OTC. What is the SEC CIK of Northwest Biotherapeutics? The SEC Central Index Key (CIK) for Northwest Biotherapeutics, Inc. is 1072379. Its filings are on SEC EDGAR. How many shares does Northwest Biotherapeutics have outstanding? 1,705,637,993 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Northwest Biotherapeutics listed under? Our directory records Northwest Biotherapeutics, Inc. under United States. What does Northwest Biotherapeutics do? Our directory classifies Northwest Biotherapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Northwest Biotherapeutics? The ISIN recorded for Northwest Biotherapeutics, Inc. is US66737P6007. Does aibio.space cover Northwest Biotherapeutics? aibio.space lists Northwest Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Northwest Biotherapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Northwest Biotherapeutics profitable? Northwest Biotherapeutics, Inc. reported a net loss of $60.2 million for the fiscal year ended Dec 31, 2025, and used $44.8 million of cash in operations, per its annual report to the SEC. How much does Northwest Biotherapeutics spend on research and development? $28.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Northwest Biotherapeutics have? $595,000 in cash at Jun 30, 2026, per its 10-Q. What is the latest Northwest Biotherapeutics (NWBO) stock news? Our latest story on Northwest Biotherapeutics, dated Jul 31, 2026: "Northwest Biotherapeutics registers 40,325,000 shares tied to $4.9 million note". Northwest Biotherapeutics signed a $4.9 million convertible note with a Yorkville fund on July 29, 2026. Net proceeds after original issue discount, a facility commitment fee and expenses are $4,655,000. [Source](https://aibio.space/news/northwest-biotherapeutics-registers-40-325-000-shares-tied-4-9-million/). What is Northwest Biotherapeutics's latest stock offering or financing news? Our latest financing story, dated Jul 31, 2026: "Northwest Biotherapeutics registers 40,325,000 shares tied to $4.9 million note". Northwest Biotherapeutics signed a $4.9 million convertible note with a Yorkville fund on July 29, 2026. Net proceeds after original issue discount, a facility commitment fee and expenses are $4,655,000. [Source](https://aibio.space/news/northwest-biotherapeutics-registers-40-325-000-shares-tied-4-9-million/). ## Investor discussion: Northwest Biotherapeutics Members talk about Northwest Biotherapeutics (NWBO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Northwest Biotherapeutics, newest first. Each line links the filing it comes from. 1. 2026-07-31 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1072379/000110465926089290/tm2621722d1_424b5.htm) 2. 2026-04-07 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01). [Source](https://www.sec.gov/Archives/edgar/data/1072379/000110465926040260/tm2611284d1_8k.htm) 3. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1072379/000110465926037871/tm2533657d2_nt10k.htm) 4. 2026-01-02 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1072379/000110465926000243/tm261685d1_8k.htm) 5. 2025-11-28 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1072379/000110465925116966/tm2530047-1_def14a.htm) 6. 2025-11-25 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1072379/000110465925116045/tm2532073d1_424b5.htm) 7. 2025-11-19 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1072379/000110465925114107/tm2530047-1_pre14a.htm) 8. 2025-08-14 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1072379/000141057825001825/nwbo-20250630x10q.htm) 9. 2025-07-01 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1072379/000110465925064804/tm2519409d1_424b5.htm) 10. 2024-12-26 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1072379/000110465924131746/tm2432020d1_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:NWBO on TradingView](https://www.tradingview.com/symbols/OTC-NWBO/). ## SEC filings and registration - **SEC name**: Northwest Biotherapeutics Inc - **CIK**: 1072379 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NWBO (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 4800 MONTGOMERY LANE, BETHESDA, MD, 20814 - **Phone**: (240) 497-9024 - **Shares outstanding**: 1,705,637,993 as of 2026-08-13 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1072379/000110465926097188/nwbo-20260630x10q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1072379/000110465926089293/tm2620800d1_8k.htm) filed 2026-07-31 - [424B5](https://www.sec.gov/Archives/edgar/data/1072379/000110465926089290/tm2621722d1_424b5.htm) filed 2026-07-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1072379/000110465926084743/tm2620800d1_8k.htm) filed 2026-07-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1072379/000110465926062661/nwbo-20260331x10q.htm) filed 2026-05-15 - [10-K](https://www.sec.gov/Archives/edgar/data/1072379/000110465926043806/nwbo-20251231x10k.htm) filed 2026-04-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1072379/000110465926040260/tm2611284d1_8k.htm) filed 2026-04-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1072379/000110465926004146/tm263317d1_8k.htm) filed 2026-01-15 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001072379), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Northwest Biotherapeutics, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker NWBO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Northwest Biotherapeutics, Inc. - **Ticker**: NWBO - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US66737P6007 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-NWBO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/northwest-biotherapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Northwest Biotherapeutics (NWBO) news: convertible notes", 2026-10-31, https://aibio.space/companies/northwest-biotherapeutics/